Previous 10 | Next 10 |
– Single Agent CFT7455 Induces Deep and Durable Degradation of IKZF1/3 and Meaningful Decreases in Serum Free Light Chain at Doses Lower than Expected Based on Pre-clinical Studies – – CFT7455 Exhibits Differentiated Pharmacokinetics (PK) and Potency Relative ...
– Utpal Koppikar, Veteran Life Sciences Industry Financial Executive, Appointed as Independent Member of the Board of Directors, Chair of Audit Committee and Member of Organization, Leadership and Compensation Committee – – Appointment Reflects C4T’s ...
The U.S. Food and Drug Administration (FDA) granted orphan drug designation to C4 Therapeutics' (NASDAQ:CCCC) CFT8634 to treat soft tissue sarcoma (STS). STS is a rare cancer that begins in the tissues — such as muscle, tendons, fat, lymph and blood vessels among others ...
WATERTOWN, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treate...
- Clinical Data from Cohort A of the Ongoing Phase 1/2 Trial of CFT7455, a Novel IKZF1/3 Degrader, Accepted as Late-Breaker Poster Presentation – - New Pre-clinical Data from CFT7455; CFT8634, a BRD9 Degrader; and CFT1946, a BRAF V600X Degrader, Accepted as Oral Presentatio...
C4 Therapeutics press release (NASDAQ:CCCC): FY GAAP EPS of -$1.82 beats by $0.27. Revenue of $45.78M (+37.9% Y/Y) beats by $12.7M. For further details see: C4 Therapeutics GAAP EPS of -$1.82 beats by $0.27, revenue of $45.78M beats by $12.7M
– Data from Cohort A of the Ongoing Phase 1/2 Trial of CFT7455, a Novel IKZF1/3 Degrader, Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting – – Pre-clinical Data on CFT7455; CFT8634, a BRD9 Degrader; and CFT194...
– Initial Phase 1 Data for CFT7455, a Novel IKZF1/3 Degrader, Expected in 1H 2022– – IND Clearance Achieved for CFT8634, a Degrader Targeting BRD9; On Track to Initiate Phase 1 Trial in Synovial Sarcoma and SMARCB1-null Solid Tumors in 1H 2022– ...
WATERTOWN, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that the Compa...
Harmony Biosciences Holdings (NASDAQ:HRMY), Aquestive Therapeutics (NASDAQ:AQST), C4 Therapeutics (NASDAQ:CCCC), Century Therapeutics (NASDAQ:IPSC), COMPASS Pathways (NASDAQ:CMPS) have been added to the Nasdaq Biotechnology Index. All the additions will be effective prior to market ...
News, Short Squeeze, Breakout and More Instantly...
WATERTOWN, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that preliminary data from the monotherapy dose escalation portion of the ongoing...
WATERTOWN, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in a fireside chat at the UBS Targeted Prote...
Cooper Brings Decades of Global Pharmaceutical and Biotechnology Leadership Experience Bruce Downey Remains a Member of the Board of Directors and Chair of the Organization, Leadership and Compensation Committee Transition Further Highlights Commitment to Strategically Transform t...